Global Safety Officer
About the job
- An M.D. degree or equivalent is required.
- For M.D. candidates, board certification or board eligibility, or equivalent, is preferred.
- At least 3 years of total experience in international pharmacovigilance or equivalent relevant industry experience, such as clinical development, with relevant clinical experience considered. Candidates with proven excellence in a similar prior position may be considered with less than 3 years of international pharmacovigilance experience.
- Demonstrate excellent clinical judgment.
- Synthesize and critically analyze data from multiple sources.
- Communicate complex clinical issues and analysis orally and in writing.
- Develop and document sound risk assessments.
- Demonstrate initiative and capacity to work under pressure.
- Demonstrate leadership within a cross-functional team environment.
- Work effectively in a team environment and demonstrate interpersonal skills.
- Fluency in spoken and written English.
- Provide pharmacovigilance and risk management expertise to internal and external customers.
- Serve as the safety expert for assigned products.
- Maintain knowledge of products, their environments, and recent literature.
- Maintain pharmacovigilance expertise and understanding of international safety regulations and guidelines.
- Lead cross-functional Safety Management Teams and Global Pharmacovigilance Excellence internal Safety Analysis Teams.
- Communicate and represent the pharmacovigilance position within project and product teams, with external partners and key opinion leaders, with health authorities, and during internal and external negotiations.
- Provide strategic and proactive safety input into development plans.
- Support due diligence activities and pharmacovigilance agreements.
- Conduct signal detection and analysis.
- Collaborate with the Center of Excellence for Signal Detection and Data Mining and the Safety Epidemiology group.
- Identify and implement proactive safety analysis strategies to further define product safety profiles.
- Lead aggregate safety data reviews and coordinate safety surveillance activities.
- Provide proactive risk assessments.
- Co-lead benefit-risk assessments with relevant functions.
- Develop risk management strategies and plans, and monitor their effectiveness.
- Collaborate with the Center of Excellence for Risk Management and Safety Epidemiology.
- Represent the safety position on cross-functional submission teams.
- Ensure the generation, consistency, and quality of safety sections in submission documents.
- Write responses or contributions to health authorities’ questions.
- Support the preparation and conduct of Advisory Committee meetings.
- Document, coordinate, review, and validate periodic reports, including Risk Management Plan updates, Investigational New Drug Annual Reports, Annual Safety Reports/Development Safety Update Reports, and Periodic Safety Update Reports.
- Serve as the medical safety expert to the Global Pharmacovigilance Excellence Periodic Reports group for assigned projects and products.
About the company
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
- June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
- Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.
What critics are saying
- Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
- Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
- Dupixent concentration makes 2030s patent loss an existential revenue shock.
What makes Sanofi unique
- Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
- October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
- Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Professional Development Budget
- Parental Leave